CXCR6 and prostate carcinoma: Elevated CXCR6 expression has been observed in various cancer tissues, including prostate cancer [32], pancreatic ductal adenocarcinoma [33], and schwannoma [34], indicating that CXCR6 could be a promising therapeutic target.